CD47 and melanoma: Studies in preclinical models with cancer types including chronic lymphocytic leukemia, colon cancer, melanoma, HNSCC, and glioblastoma, showed the induction of antitumor cytotoxic T cell populations, and reduced regulatory T cell populations in response to anti-CD47 treatment [26,55,58,59,60].